New radioactive drug targets tough prostate cancer in early trial
NCT ID NCT07537010
First seen Apr 20, 2026 · Last updated May 02, 2026 · Updated 3 times
Summary
This early study tests a new drug called 3D1015 in 8 men with a hard-to-treat type of advanced prostate cancer (mCRPC). The drug delivers a small amount of radiation directly to cancer cells. The main goals are to check safety and find the best dose. This is a first step to see if the approach might help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jiangnan University Affiliated Hospital
RECRUITINGWuxi, Jiangsu, China
Contact
Conditions
Explore the condition pages connected to this study.